Your browser doesn't support javascript.
loading
Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis.
Hisert, Katherine B; Birkland, Timothy P; Schoenfelt, Kelly Q; Long, Matthew E; Grogan, Brenda; Carter, Suzanne; Liles, W Conrad; McKone, Edward F; Becker, Lev; Manicone, Anne M.
Afiliación
  • Hisert KB; Dept of Medicine, University of Washington, Seattle, WA, USA.
  • Birkland TP; Dept of Medicine, University of Washington, Seattle, WA, USA.
  • Schoenfelt KQ; Ben May Dept for Cancer Research, University of Chicago, Chicago, IL, USA.
  • Long ME; Dept of Medicine, University of Washington, Seattle, WA, USA.
  • Grogan B; Dept of Medicine, St Vincent's University Hospital, Dublin, Ireland.
  • Carter S; Dept of Medicine, St Vincent's University Hospital, Dublin, Ireland.
  • Liles WC; Dept of Medicine, University of Washington, Seattle, WA, USA.
  • McKone EF; Dept of Medicine, St Vincent's University Hospital, Dublin, Ireland.
  • Becker L; Ben May Dept for Cancer Research, University of Chicago, Chicago, IL, USA.
  • Manicone AM; These authors contributed equally.
ERJ Open Res ; 6(2)2020 Apr.
Article en En | MEDLINE | ID: mdl-32337217
ABSTRACT
This study demonstrates that initiation of the CFTR modulator ivacaftor in people with cystic fibrosis and susceptible CFTR mutations causes an acute reduction in blood monocyte sensitivity to the key proinflammatory cytokine IFN-γ http//bit.ly/2TeI6LG.

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Año: 2020 Tipo del documento: Article